The risky business of dopamine agonists in Parkinson disease and impulse control disorders.
Keyword(s):
Keyword(s):
2012 ◽
Vol 259
(11)
◽
pp. 2269-2277
◽
2009 ◽
Vol 85
(1009)
◽
pp. 590-596
◽
Keyword(s):